STAT

Opinion: CRISPR-Cas9 commercialization may be slowed by delivery and manufacturing challenges

As the gene-editing community focuses on the ethics of using this technology, it also needs to solve the more prosaic problems of CRISPR-Cas9 delivery to cells and manufacturing.
To move gene editing toward commercialization, companies will have to solve delivery and manufacturing issues. Source: Mark Schiefelbein/AP

The news in November that a Chinese scientist may have edited the genes of embryos, resulting in the birth of two baby girls, reminds us that gene editing is still an exciting — and often controversial — field.

At the recently concluded J.P. Morgan Healthcare Conference in San Francisco, the sense of foreboding about the future of this industry had dissipated. As I spoke with my colleagues in the field and executives from other companies, I got a sense that we were confident that gene editing is poised on the edge of great success, with therapies already approved by the U.S. Food and Drug Administration and the European Medicines

You're reading a preview, sign up to read more.

More from STAT

STAT4 min read
Opinion: President Trump: Don’t Fail America’s Children On Flavored E-cigarettes
If flavors are the bait that attracts kids to e-cigarettes, nicotine is the hook. Some of the most popular e-cigarettes contain as much nicotine as a pack of cigarettes.
STAT9 min readPolitics
Elizabeth Warren’s Health Care Evolution Has Earned Her Friends On The Left, But Foes In Her Home State
Warren has shifted from a senator, sympathetic to her home state’s health care interests, to a national political figure with her sights on more sweeping policies.
STAT4 min readSociety
Opinion: Adult Vaccination Saves Lives. Why Do So Few Adults Get Vaccinated?
It's time to elevate vaccines to the scientific and technological zenith they deserve as one of the greatest advances of the 20th century, one that now has the potential to…